Genmab A+s

Staat Der Nederlanden, De Minister Van Defensie, Voor Deze: Het Hoofd

Willem Karel Bleeker

Paul Parren

Jan Van De Winkel

Patrick Van Berkel

Janine Schuurman

David Satijn

Tom Vink

Frank Beurskens

Sandra Verploegen

Aran Frank Labrijn

Ole Baadsgaard

Edward L Halk

Maroeska Oudshoorn

Rene Hoet

Arnout F Gerritsen

Rob N De Jong

Jan G J Van De Winkel

David P E Satijn

Vibeke Miller Breinholt

Eva Ehrnrooth

Mischa Houtkamp

Klaus Edvardsen

Marije Overdijk

Steen Lisby

Jorgen Petersen

Joachim Cornelis Bakker

Petrus Theodorus Biessels

Rene M A Hoet

Riemke Van Dijkhuizen

Wilhelmus Antonius Berbers

Jeroen Lammerts Van Bueren

Thomas Valerius

Michael Dechant

Wencke Weisner

Sven Berger

Rene M Hoet

David P Satijn

Rene MA Hoet

Jan GJ Van De Winkel

Marcus Antonius Van Dijk

The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Recombinant IgG4 monovalent antibodies

The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

Recombinant monovalent antibodies and methods for production thereof

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

Human antibodies against tissue factor and methods of use thereof

Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

Human antibodies and antibody-drug conjugates against CD74

The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein

Methods and antibodies for treating cancer

The described invention relates to an essentially stroma-free hemoglobin composition evidencing properties suitable for use as a universally applicable blood plasma expander and to a method for the preparation thereof. Typical, of these properties are desirable oxygen affinity values, desirable vascular retention time and substantial absence of toxic side effects. The described composition comprises human hemoglobin cross-linked intramolecularly through the beta-chains and polymerized with glutaraldehyde. Intramolecular cross-linking is typically effected with 2-nor-2-formylpyridoxal 5-phosphate or a bis-pyridoxal polyphosphate.

Hemoglobin composition and preparation thereof

Growing community of inventors

Amsterdam, Netherlands

Willem Karel Bleeker